Sterling Biotech receives NBWs in Rs 8,100-crore bank loan fraud case

A Delhi court Saturday issued open-ended non-bailable warrants (NBWs) against four directors of a Gujarat pharma firm in a Rs 8,100-crore money laundering probe case.

Additional Sessions Judge Satish Kumar Arora allowed the Enforcement Directorate’s plea seeking issuance of NBW against Sterling Biotech Ltd (SBL) directors Nitin Jayantilal Sandesara, Chetankumar Jayantilal Sandesara, Dipti Chetan Sandesara and Hiteshkumar Narendrabhai Patel.

The ED has registered the alleged bank fraud case against the firm SBL under sections of the Prevention of Money Laundering Act (PMLA).

The accused are also being probed by the ED for allegedly bribing senior income tax department officials as part of an earlier criminal complaint.

  • Related Posts

    Diabetic drug metformin found to act on brain

    NEW DELHI:  Cheap, effective and widely trusted, metformin has long been the first choice for treating type 2 diabetes. Now, scientists say the drug works in a way few had…

    Hetero debuts semaglutide generic in emerging markets

    New Delhi: Hyderabad-based drugmaker Hetero has announced the launch of its generic semaglutide portfolio in emerging international markets. In a phased global push, the company plans to roll out its…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Diabetic drug metformin found to act on brain

    Diabetic drug metformin found to act on brain

    Hetero debuts semaglutide generic in emerging markets

    Hetero debuts semaglutide generic in emerging markets

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework